Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome.
OBJECTIVE
The aim of this study was to assess the impact of alosetron, a treatment recently approved in the United States for irritable bowel syndrome in diarrhea-predominant female patients, on health-related quality of life.


METHODS
Quality of life was assessed as part of two 12-wk randomized, double-blind, placebo-controlled irritable bowel syndrome studies comparing alosetron 1 mg b.i.d. with placebo (S3BA3001 and S3BA3002). Patients completed a validated disease-specific quality of life questionnaire, the Irritable Bowel Syndrome Quality of Life Questionnaire (IBSQOL), at baseline and at the 12-wk or final visit. The clinical relevance of data were also evaluated by a minimal meaningful difference instrument.


RESULTS
A total of 626 and 647 patients were enrolled in studies S3BA3001 and S3BA3002, respectively. Approximately 70% of patients in each study had diarrhea-predominant IBS. In diarrhea-predominant patients enrolled in S3BA3001, statistically significant (p < 0.05) improvements with alosetron versus placebo were observed on all nine IBSQOL scales (emotional health, mental health, sleep, energy, physical functioning, food/diet, social functioning, role-physical, and sexual relations) and for all but one scale (mental health) in S3BA3002. In both studies, a significantly greater percentage of patients treated with alosetron (p < 0.05) experienced clinically meaningful improvement on three of the nine IBSQOL scales (food/diet, social functioning, and role-physical) compared with patients treated with placebo. Patients treated with alosetron did not show worsening in any quality of life domain compared with patients treated with placebo.


CONCLUSIONS
These results in women with diarrhea-predominant IBS demonstrate that alosetron significantly improves health-related quality of life.
Global Health Outcomes, Glaxo Wellcome, Research Triangle Park, North Carolina 27709-3398, USA.
M E
ME
Watson
L
L
Lacey
S
S
Kong
A R
AR
Northcutt
D
D
McSorley
B
B
Hahn
A W
AW
Mangel
D002243:Carbolines / Q000627:therapeutic use*; D003109:Colonic Diseases, Functional / Q000188:drug therapy* / Q000523:psychology*; D003967:Diarrhea / Q000517:prevention & control*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008875:Middle Aged; D011788:Quality of Life; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D013997:Time Factors
D002243:Carbolines; D012702:Serotonin Antagonists; C090840:alosetron